Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma

Summary

The primary objective of this study is to assess the efficacy (bronchoprotection) and safety of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the Respimat® inhaler, in patients with intermittent asthma.

Timeline

Start

2006-01

Primary completion

2006-10

Completion

—

Outcome

Met primary endpoint

registry Placebo vs Olodaterol (Olo) 2 mcg qd; p <0.0001; Mean Difference (Final Values) 1.157 (95% CI 0.657 to 1.657); Mixed Models Analysis NCT00928668 ↗

Drugs

Indications